Search Medical Condition
Please enter condition
Please choose location from dropdown
 

L'Hospitalet de Llobregat-Barcelona, Spain Clinical Trials

A listing of L'Hospitalet de Llobregat-Barcelona, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (880) clinical trials

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT ...

Phase

0.0 miles

Learn More »

Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia

This is an observational, non-interventional study that will include two cohorts of patients with schizophrenia who initiated maintenance treatment during a schizophrenia-related hospitalisation: patients who initiated maintenance treatment with aripiprazole once-monthly and patients who initiated maintenance treatment with any daily oral atypical antipsychotic. The date of maintenance treatment initiation will ...

Phase N/A

0.0 miles

Learn More »

Firazyr Patient Registry (Icatibant Outcome Survey - IOS)

The Firazyr and Cinryze patient registry is a multicenter, prospective, observational study for patients treated with Firazyr and/or Cinryze in countries where it is currently approved. The entry of participants in the Firazyr and Cinryze Registry is at the discretion of the physician and the participant and is not a ...

Phase N/A

0.0 miles

Learn More »

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

A good proportion of patients with chronic lymphocytic leukemia (CLL) can be managed effectively with palliative chemotherapy. However, there is a group of younger patients with poor risk disease whose life expectancy is significantly reduced. As a result, reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (allo-HCT) has been investigated ...

Phase

0.0 miles

Learn More »

Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF

Multicenter, prospective, observational study for evaluating if circulant rheumatoid factor, cyclic citrullinated anti-peptide anti-bodies and albumin can be used as potential predictors in the response to the treatment with anti-TNF in patients with rheumatoid arthritis after 24 weeks of treatment.

Phase N/A

0.0 miles

Learn More »

Effectiveness of an Intensive Weight Loss Program for Obstructive Sleep Apnea Syndrome (OSAS) Treatment.

Calculating the sample size: The primary endpoint is the reduction of final apnea-hypopnea index (AHI) with respect to baseline. Assuming an alpha level of 0.05 and a bilateral approach to have 80% statistical power, the investigators estimate a final sample size of 42 patients is required to detect a 15 ...

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Amantadine HCl ER has been used for many years as a treatment for Parkinson's disease. It has been reported in the literature to effectively treat the motor complications of levodopa, especially dyskinesia, but it must be given 2 to 4 times a day. The purpose of this multi-center, randomized, double-blind, ...

Phase

0.0 miles

Learn More »

Phase

0.0 miles

Learn More »

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

- To determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias. - To determine the 2 and 3 year rate of locoregional disease control. - To evaluate the safety and toxicity of the combination of cetuximab and concomitant-boost accelerated ...

Phase

0.0 miles

Learn More »